Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 20/20 | 0.70 |
| ▸ | SLC16A1 | P53985 | 19/20 | 0.70 |
| ▸ | MCTS1 | Q9ULC4 | 12/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29819644 | 1.00 | SLC16A3 (0.70) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL29487685 | 0.92 | SLC16A3 (0.66) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL20239564 | 0.91 | SLC16A3 (0.80) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL20239622 | 0.86 | SLC16A3 (0.85) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL31130177 | 0.86 | SLC16A3 (0.85) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL18307411 | 0.84 | SLC16A3 (0.83) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL31130146 | 0.83 | SLC16A3 (0.84) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL18307500 | 0.82 | SLC16A3 (0.87) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL18300861 | 0.82 | SLC16A3 (1.00) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL29487692 | 0.82 | SLC16A3 (1.00) | SLC16A3SLC16A1MCTS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-110114351-B | Heterocyclic inhibitors of MCT4 | 维托尔股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3551625-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | SLC16A3 1/4885SLC16A1 2/4885MCTS1 3/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | SLC16A3 2/4885SLC16A1 1/4885MCTS1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.